Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha

Απλή σελίδα τεκμηρίου
dc.contributor.authorChristodoulou, D.en
dc.contributor.authorChristou, L.en
dc.contributor.authorZervou, E.en
dc.contributor.authorKatsanos, K.en
dc.contributor.authorKitsanou, M.en
dc.contributor.authorTsianos, E. V.en
dc.date.accessioned2015-11-24T19:35:56Z
dc.date.available2015-11-24T19:35:56Z
dc.identifier.issn0172-6390-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23772
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntibodies/*chemistryen
dc.subjectAutoantibodies/blooden
dc.subjectBlood Platelets/*immunologyen
dc.subjectCell Adhesionen
dc.subjectFemaleen
dc.subjectFluorescent Antibody Technique, Indirecten
dc.subjectHepatitis B/*immunology/therapyen
dc.subjectHepatitis C/*immunologyen
dc.subjectHepatitis, Viral, Human/*immunologyen
dc.subjectHumansen
dc.subjectImmunoglobulin G/*chemistryen
dc.subjectInterferon-alpha/*therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectSpleen/ultrasonographyen
dc.subjectThrombocytopenia/etiologyen
dc.subjectTreatment Outcomeen
dc.titleAntiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alphaen
heal.abstractBACKGROUND/AIMS: The aim of this study was to investigate the possible role of interferon-alpha in the development of antiplatelet IgG antibodies in patients with chronic viral hepatitis B or C. METHODOLOGY: Ninety-one consecutive patients with chronic viral hepatitis (51 with chronic hepatitis B and 40 with chronic hepatitis C) were investigated for the presence of antiplatelet IgG antibodies in their serum immediately prior to IFN-alpha therapy and after six months of therapy. The method used was the solid phase red cell adherence test (Immucor, Norcross, USA), which is a sensitive tracer of antiplatelet antibodies. Some of the results were confirmed using an indirect immunofluorescence test for the detection of antiplatelet antibodies RESULTS: Overall, we found that antiplatelet antibodies were present in 37.54% (19/51) of patients with chronic hepatitis B before IFN-alpha therapy and in 35.29% (18/51) after therapy. Moreover, antiplatelet antibodies were found in 20% (8/40) of patients with chronic hepatitis C before and after IFN-alpha therapy. CONCLUSIONS: Therapy with IFN-alpha did not induce antiplatelet antibodies in patients with chronic viral hepatitis B or C. Thrombocytopenia observed during IFN-alpha therapy in our study was not due to the development of antiplatelet antibodies.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18019713-
heal.journalNameHepatogastroenterologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ